Discontinued Development – Isradipine

Isradipine was one of two products in an agreement with Mikah Pharma that was intended to be transferred to Elite for manufacture. (Phendimetrazine was the second product) Preliminary production batches of Isradipine at Elite, using the equipment provided in the agreement, did not produce acceptable product. Mikah and Elite therefore mutually agreed in an amendment to the agreement to discontinue transfer of the Isradipine.

I'd like to hear more about why Isradipine could not be produced acceptably with the equipment provided?.....and then who will get Isradipine and why wouldn't Elite try to produce Isradipine with different equipment then?